Helix Biopharma Corp.
HBP.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -70.26% | -55.31% | -44.77% | -9.59% | 0.61% |
| Total Depreciation and Amortization | -8.74% | -0.97% | 5.15% | 22.22% | 11.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 601.36% | 495.63% | 512.10% | 119.37% | -22.93% |
| Change in Net Operating Assets | 321.60% | 392.04% | 146.50% | 34.25% | -13.77% |
| Cash from Operations | 43.66% | 29.88% | 6.64% | -1.68% | -4.12% |
| Capital Expenditure | 69.79% | 87.29% | -37.33% | -43.28% | -43.28% |
| Sale of Property, Plant, and Equipment | 267.57% | 59.46% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 284.48% | 155.00% | -178.38% | 13.43% | 13.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 116.45% | 116.45% |
| Issuance of Common Stock | 46.91% | -24.90% | -9.80% | -33.26% | -66.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.58% | -12.67% | 74.34% | -1.13% | -57.62% |
| Foreign Exchange rate Adjustments | 85.07% | -130.29% | 0.00% | -1,360.00% | 177.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 166.03% | 48.95% | 110.69% | -36.22% | -207.24% |